Nick Rose @Asinickle1 has been doing a fantastic job keeping track of JN.1, and has also been estimating growth. We are arriving at close to the same numbers.
There's a new study claiming no increased risk of new any type infection after covid infection. I don't have a strong opinion on either side of this argument at this point. Let's take an objective look at what this study actually shows (TLDR, it's poor): academic.oup.com/cid/advance-ar…
Right off the bat there is a glaring issue. As @DGBassani points out, the control group (uninfected) has more than 3x the deaths as the covid infected group. And there's more, far more comorbidities and +5 years. That's a terrible control group.
They also intentionally removed anyone with more than 1 covid infection from the data (?? You'd think they might be important to this study, no?)
One would think maybe those people were the most likely to have had some immune disfunction. But they were slashed from the results.
BA.2.86 Pirola's global growth advantage is becoming more clear. I excluded South Africa's data (way too messy), and the UK care home cluster.
Estimated weekly advantage is 74%, with a 50% CI of 56-96%.
If this holds, it would suggest Pirola outcompetes the strongest FLips.
The biggest uncertainty to me still lies in the randomness of sampling. It's unclear it some samples are being sequenced due to SGTF, or more importantly, if that has changed in the past month.
I agree with @Asinickle1 estimate in Denmark. Just not convinced yet that Denmark will be representative of the world's varied immune history. We will see if it is or not in coming months.
Prediction is difficult at the moment with a lot of factors at play, so this is a range for now. Peaks are always hard to predict.
Lower model run peaks this week. FLip is growing, but not fast enough to peak later than late Sept.
FLip, and HV.1 with L452R (last seen in Delta and BA.5*) are growing, with HV.1 and HK.3 being the fastest at the moment. They probably won't come into play until late Oct/Nov, likely starting a new wave.
Still waiting to see how Ba.2.86 Pirola evolves and moves.
This range translates to a max of ~720-900k cases per day for this wave on the wastewater calibration curve.
For sake of comparison, what happened with Omicron? A thread:
First, we had 3 highly mutated sequences from Botswana/South Africa. Within a few days we had enough data from SA to estimate growth advantage of 500% 1/
Then, we were able to see quick case growth in South Africa. The case growth roughly agreed with the advantage estimate. A couple days after this the Re increased to 3.6. 2/